Reseach progress on the role of ErbB2 in cardiac disease
10.12092/j.issn.1009-2501.2022.10.013
- Author:
Yunjie CHEN
1
;
Xuan ZHOU
1
;
Yuanbin ZHANG
1
;
Zhu LIN
1
;
Suyan ZHU
1
;
Yunjie CHEN
2
;
Xu WANG
2
Author Information
1. Department of Pharmacy, Ningbo First HospitaI
2. SchooI of PharmaceuticaI Science, Wenzhou MedicaI University
- Publication Type:Journal Article
- Keywords:
cardiac disease;
diagnostic marker;
ErbB2;
therapeutic target
- From:
Chinese Journal of Clinical Pharmacology and Therapeutics
2022;27(10):1182-1189
- CountryChina
- Language:Chinese
-
Abstract:
Cardiac disease is the general term of diseases, caused by damage to the structure or abnormal function of the heart. Its morbidity and mortality have remained high, seriously threatening the lives and health of people. The tyrosine kinase receptor ErbB2 (also known as EGFR2 or HER2) was originally discovered for its oncogenic activity, however, recent studies have found that ErbB2 have protective effects in various heart diseases. Therefore, this article reviews the role and underlying mechanism of ErbB2 in myocardial infarction, myocardial ischemia/reperfusion injury, cardiac hypertrophy, heart failure, doxorubicin-induced cardiotoxic injury and diabetic cardiomyopathy. Furthermore, this article also preliminarily discusses the application prospects, limitations and development directions of ErbB2 as a clinical diagnostic marker and therapeutic target for heart disease.
